Skip to main content

Jupiter Neurosciences Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.

Current Price

$0.24

+16.93%
Profile
Valuation (TTM)
Market Cap$7.06M
P/E-0.77
EV
P/B
Shares Out29.44M
P/Sales174.48
Revenue$40448.00
EV/EBITDA

JUNS (JUNS) — Earnings Call Transcripts

No transcripts available yet

No earnings call transcripts are available for JUNS yet. Check back after the next earnings report.

← Back to JUNS overview